Adularia: A New Chapter in Oncology Innovation

We are excited to announce that Recolony is now Adularia. This change reflects an important shift in our company’s strategic direction and our ongoing commitment to advancing cancer treatments.

Originally focused on developing a Live Biotherapeutic Product (LBP) from the microbiome, we have made a groundbreaking discovery: the mechanism behind the anti-tumor effects observed with our bacterial product. As a result, we have pivoted our research focus to the development of a small molecule that targets the same mechanism, providing a more defined and targeted approach to oncology therapy.

This strategic shift marks a new era for our company. With a clearly defined molecule rather than a complex organism, we are better positioned to drive innovation in oncology and deliver more effective treatments to patients.

The decision to change our company name was driven by the need for a brand that more accurately reflects our broadened focus. Our former name, Recolony, was closely tied to our initial microbiome-based approach, and as we transitioned to small molecule development, we felt it was important to adopt a name that encompasses our new direction and the broader potential of our pipeline.

Along with our name change, we are also unveiling a refreshed visual identity, which symbolizes the forward-looking vision we are embracing.

We are incredibly excited about this new phase and the opportunities it brings, and we remain dedicated to advancing impactful oncology therapies. Thank you for your continued support as we work to shape the future of cancer treatment.

Stay tuned for more updates as we continue to innovate and grow.

Learn more on the new website